Currently, sabatolimab (high-affinity IgG4 mAb) is the only anti–TIM-3 mAb being investigated in MDS and acute myeloid leukemia (AML) with preliminary safety and efficacy data. Here, HAVCR2 is linked to myelodysplastic syndrome.